Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) Equity Ratio (2021 - 2026)

bioAffinity Technologies has reported Equity Ratio over the past 6 years, most recently at 0.46 for Q1 2026.

  • Quarterly Equity Ratio rose 77.6% to 0.46 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 0.46 through Mar 2026, up 77.6% year-over-year, with the annual reading at 0.66 for FY2025, 66.21% up from the prior year.
  • Equity Ratio was 0.46 for Q1 2026 at bioAffinity Technologies, down from 0.66 in the prior quarter.
  • Over five years, Equity Ratio peaked at 0.92 in Q1 2023 and troughed at 0.45 in Q2 2025.
  • The 5-year median for Equity Ratio is 0.65 (2024), against an average of 0.58.
  • Year-over-year, Equity Ratio soared 108.34% in 2022 and then tumbled 187.17% in 2025.
  • A 5-year view of Equity Ratio shows it stood at 0.91 in 2022, then plummeted by 34.86% to 0.59 in 2023, then plummeted by 32.36% to 0.4 in 2024, then skyrocketed by 66.21% to 0.66 in 2025, then crashed by 30.6% to 0.46 in 2026.
  • Per Business Quant, the three most recent readings for BIAF's Equity Ratio are 0.46 (Q1 2026), 0.66 (Q4 2025), and 0.77 (Q3 2025).